First Republic Investment Management Inc. raised its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 8.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 111,204 shares of the pharmaceutical company’s stock after purchasing an additional 8,341 shares during the period. First Republic Investment Management Inc.’s holdings in GlaxoSmithKline were worth $4,515,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also added to or reduced their stakes in the business. Proficio Capital Partners LLC increased its stake in shares of GlaxoSmithKline by 16.1% in the 2nd quarter. Proficio Capital Partners LLC now owns 3,301 shares of the pharmaceutical company’s stock valued at $135,000 after acquiring an additional 457 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its stake in shares of GlaxoSmithKline by 1.9% in the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock valued at $137,000 after acquiring an additional 64 shares during the last quarter. FTB Advisors Inc. increased its stake in shares of GlaxoSmithKline by 16.9% in the 2nd quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock valued at $146,000 after acquiring an additional 539 shares during the last quarter. Quadrant Capital Group LLC increased its stake in shares of GlaxoSmithKline by 3.5% in the 2nd quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock valued at $162,000 after acquiring an additional 148 shares during the last quarter. Finally, Parallel Advisors LLC increased its stake in shares of GlaxoSmithKline by 93.4% in the 2nd quarter. Parallel Advisors LLC now owns 4,048 shares of the pharmaceutical company’s stock valued at $164,000 after acquiring an additional 1,955 shares during the last quarter. Institutional investors own 9.83% of the company’s stock.
In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the stock in a transaction that occurred on Monday, November 6th. The stock was acquired at an average cost of $14.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 10.00% of the stock is currently owned by corporate insiders.
GlaxoSmithKline plc (GSK) traded up $0.33 during midday trading on Monday, reaching $35.17. The company had a trading volume of 4,530,500 shares, compared to its average volume of 3,524,805. GlaxoSmithKline plc has a twelve month low of $34.52 and a twelve month high of $44.53. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. The company has a market cap of $86,495.23, a PE ratio of 12.47, a price-to-earnings-growth ratio of 1.95 and a beta of 0.98.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be paid a dividend of $0.5037 per share. This represents a $2.01 dividend on an annualized basis and a yield of 5.73%. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date is Thursday, November 9th. GlaxoSmithKline’s dividend payout ratio is presently 163.12%.
GSK has been the subject of a number of recent analyst reports. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research note on Wednesday, October 18th. Morgan Stanley cut GlaxoSmithKline from an “equal weight” rating to an “underweight” rating in a research note on Friday, September 8th. Argus reissued a “buy” rating and set a $50.00 target price on shares of GlaxoSmithKline in a research note on Thursday, August 31st. TheStreet raised GlaxoSmithKline from a “c+” rating to a “b” rating in a research note on Wednesday, October 25th. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, October 24th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $39.71.
COPYRIGHT VIOLATION NOTICE: “First Republic Investment Management Inc. Grows Holdings in GlaxoSmithKline plc (GSK)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/11/first-republic-investment-management-inc-grows-holdings-in-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.